Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06097273 · ClinicalTrials.gov registry record · Phase 3
A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age
A Phase 3 study, sponsored by ModernaTX.
- Completed
- Registry status
- Phase 3
- Development phase
- 8,061
- Enrollment target
NCT06097273 is a Phase 3 study that has completed, run by ModernaTX. The registered enrollment target is 8,061 participants.
The verdict
NCT06097273, a Phase 3 study, has completed, sponsored by ModernaTX.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 8,061 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the immunogenicity, safety, and reactogenicity of mRNA-1083 as compared with active control, co-administered licensed influenza and severe acute respiratory syndrome coronavirus 2 (SARS CoV 2) vaccines, in 2 independent age-group sub-study cohorts, healthy adults 65 years and older (Cohort A) and healthy adults 50 to \<65 years of age (Cohort B).
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Influenza Vaccine
- BIOLOGICAL COVID-19 Vaccine
- BIOLOGICAL mRNA-1083
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8,061 participants |
| Start Date | 2023-10-19 |
| Est. Completion | 2024-05-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06097273
The ClinicalTrials.gov registry entry for NCT06097273 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 8,061 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ModernaTX, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT06097273 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06097273 about?
NCT06097273 is a clinical study titled "A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age". The purpose of this study is to evaluate the immunogenicity, safety, and reactogenicity of mRNA-1083 as compared with active control, co-administered licensed influenza and severe acute respiratory syndrome coronavirus 2 (SARS CoV 2) vaccines, in 2 independent age-group sub-study cohorts, healthy ad...
What is the current status of trial NCT06097273?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 8,061 participants. The study started on 2023-10-19. Estimated completion is 2024-05-28.
What interventions are being tested in trial NCT06097273?
The interventions under investigation include: Placebo (BIOLOGICAL), Influenza Vaccine (BIOLOGICAL), COVID-19 Vaccine (BIOLOGICAL), mRNA-1083 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06097273?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.